Gibson Dunn Antitrust Team Advises Merck on $6.7 Billion Acquisition of Terns Pharmaceuticals, Inc.

Merck is receiving advice from a Gibson Dunn antitrust team about its $6.7 billion purchase of the clinical-stage oncology business Terns Pharmaceuticals, Inc. With TERN-701, a possible best-in-class option for the treatment of some patients with chronic myeloid leukemia, Merck’s expanding presence in hematology is strengthened by the purchase of Terns.